MODEL VERDICT
RAPT Therapeutics, Inc. (RAPT) — Relative Valuation
Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Popular:
Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Composite score derived from valuation, quality, and risk factors
Quantitative model thresholds · For educational and research purposes only
Each row records the model's monthly assessment. High Conviction = the model detected notable undervaluation vs peers. Neutral = no notable divergence was found. The return column shows the actual price change over 90 days for reference. This is a quantitative observation log — not investment advice.
| Date | Assessment | Score | Price | Status | 90d Fwd Return |
|---|---|---|---|---|---|
| Jan 11, 2026 | MODERATE | 0.65 | $33.62 | CURRENT | +71.8% |
| Dec 12, 2025 | MODERATE | 0.65 | $36.80 | Pending | +57.0% |
| Nov 12, 2025 | MODERATE | 0.65 | $29.40 | Scaled in | +96.5% |
| Oct 13, 2025 | MODERATE | 0.65 | $26.35 | Scaled in | +27.6% |
| Sep 13, 2025 | MODERATE | 0.64 | $16.22 | Scaled in | +126.9% |
Historical model observations for research purposes only. Past quantitative patterns do not predict future results. Not a recommendation to buy, sell, or hold any security.
Cross-sectional regression predicting expected multiples based on growth, margins, ROIC, and beta.
| Multiple | Avg | Median | Min | Max | Std |
|---|---|---|---|---|---|
| P/TBV | 4.61 | 4.99 | 0.34 | 8.24 | 2.81 |
| P/B Ratio | 4.61 | 4.99 | 0.34 | 8.24 | 2.81 |
| P/S Ratio | 260.11 | 263.85 | 94.54 | 421.94 | 163.73 |
Insufficient data to determine relative valuation for RAPT.
Fair value could not be computed for RAPT due to insufficient comparable data.
RAPT's current P/E of -2.3x compares to the industry median of 21.4x (48 peers in the group). This represents a -110.6% discount to the industry. The historical average P/E is N/Ax over 0 years. Signal: Deep Discount.
15 analysts cover RAPT with a consensus rating of Hold. The consensus price target is $60.00 (range: $58.00 — $70.00), implying +3.5% upside from the current price. Grade breakdown: Strong Buy (0), Buy (4), Hold (11), Sell (0), Strong Sell (0).
The model confidence score is 49/100, based on: data completeness (0), peer quality (25), historical depth (16), earnings stability (5), and model agreement (3). Cyclicality penalty: -0 points. The model shows moderate agreement across inputs.
The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.
Peak earnings risk data is not available for RAPT.
No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.